newsfilter
← Latest News
ACCESS Newswire·

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. , a